Skip to main content
VXRT
OTC Life Sciences

Vaxart Q3 Revenue Falls to $10.6M; Cash Runway Into Q2 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.365
Mkt Cap
$88.635M
52W Low
$0.32
52W High
$0.845
52W Position info
14% above low
Off High info
57% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

VXRT is trading near its 52-week low of $0.32 (14% above the low).

Summary

Vaxart posted Q3 2026 revenue of $10.6M versus $72.4M a year earlier and a $17.7M net loss, with $65.5M in cash that it says lasts into Q2 2027 — short of the mid-2027 Phase 2b COVID-19 data readout.


Key Events · Earnings and Guidance · VXRT

  • Q3 Revenue Drops to $10.6M

    Revenue fell from $72.4M in Q3 2025 to $10.6M in Q3 2026, primarily BARDA contract revenue, with Q3 2026 also including Dynavax license revenue.

  • Net Loss Widens to $17.7M

    Net loss was $17.7M, or ($0.07) per share, versus $8.1M, or ($0.04) per share, a year earlier; R&D fell to $22.8M from $75.9M.

  • Cash Runway Into Q2 2027

    Cash, cash equivalents and short-term investments totaled $65.5M at September 30, 2026, which management says funds operations into Q2 2027.

  • COVID Data Now Mid-2027

    Topline efficacy and safety data from the 400-person sentinel cohort and roughly 5,000 main-cohort patients are now expected by mid-year 2027, after the stated runway ends.


Analysis · VXRT · Life Sciences

The revenue collapse to $10.6M from $72.4M a year ago reflects a heavy BARDA contract billing surge in the prior-year quarter, and the net loss widened to $17.7M from $8.1M. What matters most is the $65.5M of cash and investments, which management says funds operations only into the second quarter of 2027 — before the Phase 2b COVID-19 topline readout now guided to mid-year 2027. That gap means another raise or a partnership is likely needed to reach the data, and the company says it is pursuing business development and non-dilutive funding. The $49.7M at-the-market program established in May 2026 remains the most obvious dilution channel.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VXRT was trading at $0.37 on OTC in the Life Sciences sector, with a market capitalization of approximately $88.6M. The 52-week trading range was $0.32 to $0.84. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VXRT - Latest Insights

VXRT
Nov 05, 2026, 4:26 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.360 info
Change: -$0.0050 (-1%) info
Market Cap: $87.733M info
VXRT
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.360 info
Change: -$0.0050 (-1%) info
Market Cap: $87.733M info
VXRT
Jul 17, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.515
Real-time Price: $0.360 info
Change: -$0.155 (-30%) info
Market Cap: $87.733M info
VXRT
Jul 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.584
Real-time Price: $0.360 info
Change: -$0.224 (-38%) info
Market Cap: $87.733M info
VXRT
Jul 06, 2026, 6:09 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $0.584
Real-time Price: $0.360 info
Change: -$0.224 (-38%) info
Market Cap: $87.733M info